All the news Showing 10 of 83 articles from: Ns5A inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Novartis ends hepatitis C pact with Enanta Pharma Times / 02 October 2014 J&J makes a splash in hep C with a $1.75B deal for Alios Fierce Biotech / 01 October 2014 European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults Gilead press release / 29 September 2014 AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials HIVandHepatitis.com / 15 September 2014 Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C Fierce PharmaMarketing / 11 September 2014 European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection Bristol-Myers Squibb / 27 August 2014 Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen Bristol-Myers Squibb press release / 08 July 2014 Daclatasvir + asunaprevir is highly effective against hepatitis C genotype 1b HIVandHepatitis.com / 13 June 2014 Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV Achillion press release / 10 June 2014 Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C Forbes / 09 June 2014 ← Prev1...23456...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive